Forty51 Ventures
Overview
Forty51 Ventures is a Basel-based venture capital firm specializing in early-stage biotech investments across Europe. The firm focuses on company formation and early-stage investments in biotech, with a geographic emphasis on Switzerland, France, and Germany. Forty51 Ventures leads or co-leads early rounds (Seed and Series A) of its growing portfolio, which includes both academic and pharma spin-outs. The firm's investment strategy is therapeutic area agnostic, with a preference for central nervous system (CNS) disorders, oncology, immunology and inflammation, fibrotic disorders, and ophthalmology. Forty51 Ventures aims to be the first institutional investor in biotech companies, supporting entrepreneurs in their journey of venture creation. Founded in April 2022, Forty51 Ventures closed its first fund, Forty51 Ventures I, in July 2022, raising USD 43 million. The fund is advised by a complementary founding team of industry veterans, including Sara Núñez-García, Sascha Oliver Bucher, and Tamás Schweighoffer, who bring decades of drug development, transactions, and venture expertise. The firm is anchored by a strong institutional investor syndicate with Stable Asset Management and the Fischli Family, among others.
Investment Focus
- Clear path to the clinic
- First or best-in-class potential
- Therapeutic areas of interest: CNS, oncology, immunology and inflammation, fibrotic disorders, ophthalmology
Portfolio Companies
Reach Forty51 Ventures directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Forty51 Ventures
What sectors does Forty51 Ventures invest in?
Forty51 Ventures invests in Healthcare, Biotechnology, Therapeutics and Medical, and is based in Basel-Stadt, Switzerland. Forty51 Ventures is listed as a venture capital in the ConnectSafely investor database.
What stage does Forty51 Ventures invest at?
Forty51 Ventures backs companies at Pre-Seed and Seed, writing cheques of 1.5M - 3M.
Which regions does Forty51 Ventures invest in?
Forty51 Ventures invests across Germany, France and Switzerland.
Who are the partners at Forty51 Ventures?
Team members listed for Forty51 Ventures include Lilly Lilly (CEO) and Darren Ji (CEO).
What companies has Forty51 Ventures invested in?
Forty51 Ventures's portfolio includes Mosanna Therapeutics, Allegria Therapeutics and Mysthera Therapeutics.
How do I contact Forty51 Ventures?
Forty51 Ventures's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
